GNTA vs. TCRX, ACIU, EDIT, ACB, ALIM, JSPR, AKBA, RNAC, HRTX, and ADAP
Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include TScan Therapeutics (TCRX), AC Immune (ACIU), Editas Medicine (EDIT), Aurora Cannabis (ACB), Alimera Sciences (ALIM), Jasper Therapeutics (JSPR), Akebia Therapeutics (AKBA), Cartesian Therapeutics (RNAC), Heron Therapeutics (HRTX), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry.
TScan Therapeutics (NASDAQ:TCRX) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
Genenta Science has a net margin of 0.00% compared to TScan Therapeutics' net margin of -855.84%. Genenta Science's return on equity of 0.00% beat TScan Therapeutics' return on equity.
TScan Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.
In the previous week, TScan Therapeutics' average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.
Genenta Science has lower revenue, but higher earnings than TScan Therapeutics.
TScan Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 102.70%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 492.42%. Given Genenta Science's higher possible upside, analysts plainly believe Genenta Science is more favorable than TScan Therapeutics.
TScan Therapeutics received 21 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 77.14% of users gave TScan Therapeutics an outperform vote.
82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 2.8% of TScan Therapeutics shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Genenta Science beats TScan Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Genenta Science News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genenta Science Competitors List
Related Companies and Tools
